


April 2026 edition

Dear collaborators, partners, and members of the MoLBi community,

April has been a milestone month for the Monash Live-Biobanking platform, marked by continued growth in tumour collection, important progress toward early phase clinical translation, and expanding national and international collaborations across the MoLBi research network.

On 30 March, the platform reached an important achievement with the enrolment of **our 250th participant**, reflecting the sustained efforts of our neurosurgical teams, theatre and nursing staff, research coordinators, and animal facility colleagues who make real-time tumour collection possible. Since reaching this milestone, recruitment has continued strongly and the platform now **includes 263 cases**, reinforcing the momentum of MoLBi as one of the fastest growing live-tumour biobanking initiatives in Australia.



A major step forward this month was the formal submission of the MoLBi Phase Zero platform study to the **Human Research Ethics Committee on 21 April**. This represents an important transition for MoLBi from discovery infrastructure toward early clinical translation, enabling rapid evaluation of investigational therapies within the surgical treatment window and supporting multiple future investigator-led and industry-supported sub-studies.

Our April MoLBi Translational Research Platform Meeting brought together collaborators across clinical, laboratory, engineering, and computational disciplines. We were delighted to welcome **Sarah Tozer** as a new consumer partner joining the MoLBi community, further strengthening the central role of patient and family perspectives in shaping the direction of the platform.



A highlight of the meeting was a presentation from **Professor Victor Puelles**, who joined remotely from Denmark to introduce his work on building scalable spatial protein atlases from clinical pathology specimens. His group's advances in multiplex spatial proteomics provide exciting opportunities to integrate high-dimensional protein mapping with MoLBi biospecimens and support future national translational infrastructure initiatives.

Following the meeting, we were pleased to have a dialogue with **Paul Mirabelle**, a member of the Executive Board of Tour de Cure, whose longstanding leadership experience across the healthcare sector and commitment to supporting cancer research highlight the importance of philanthropic partnerships in enabling investigator-initiated innovation.

Alongside these developments, the MoLBi team continues to be actively engaged in a busy grant submission period, including contributions to two NHMRC Ideas Grant applications, an ACRF application to establish a major research infrastructure platform at the Monash Health Translation Precinct (MHTP), and the MRFF Australian Brain Cancer Mission, reflecting growing recognition of MoLBi as a clinically embedded translational research infrastructure supporting precision oncology discovery.

As the platform continues to expand, we remain focused on strengthening the bridge between surgery and science, enabling advanced molecular and spatial profiling, and accelerating translation into early phase clinical trials and bespoke therapy programs for patients with difficult-to-treat cancers.

Thank you, as always, to our clinicians, researchers, students, consumers, collaborators, and partners whose continued commitment drives the success of the MoLBi platform.

With best wishes,



Dr Gwo Yaw Ho
Founder and Chair, Monash Live-Biobanking



Professor Justin Moore
Director of Neurosurgery, Monash Health